Early diagnosis and treatment of invasive aspergillosis as a main determinant of outcome - review of literature according to the presented case report
- PMID: 28378982
- DOI: 10.5604/12321966.1233966
Early diagnosis and treatment of invasive aspergillosis as a main determinant of outcome - review of literature according to the presented case report
Abstract
Although. Aspergillus spp infection is not the major cause of morbidity in Intensive Care Units (ICUs), mortality among patients treated for it is tremendous. Moreover, invasive aspergillosis (IA) is an independent risk factor of hospital costs and length of stay. The prevalence of this disease is inversely correlated with the immunocompetence of individuals; for instance, the incidence of IA among patients with leukemia is estimated as high as 12.7%. Although there is a significant improvement in the antifungal armamentarium, the appropriate treatment is still being given too late, mostly because of late diagnosis. As well as the diagnosis, the criteria for recognition of IA constitute a challenge.
Objective: The aim of this review, based on a case report, is to introduce the problem of poor diagnosis and treatment of IA, especially in the critical care settings. The presented scenario is an example which assists in showing the evidence-based medicine (EBM) approach to the treatment of fungal infections. Furthermore, to demonstrate the appropriate approach to diagnosis and treatment of invasive aspergillosis, the guidelines of The European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) are presented.
Conclusions: According to presented literature, Galactomannan assay enables early diagnosis and remains a specific and sensitive tool to diagnose Asppergillosis, both in serum and BAL fluid. The guidelines recommend voriconazole as a first line treatment in IA. Failure to detect and implement proper antifungal treatment may lead to fatal consequences, as in the presented case.
Similar articles
-
Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study.Clin Microbiol Infect. 2016 Oct;22(10):862-868. doi: 10.1016/j.cmi.2016.06.021. Epub 2016 Jul 5. Clin Microbiol Infect. 2016. PMID: 27393123
-
Invasive mould infections in the ICU setting: complexities and solutions.J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i39-i47. doi: 10.1093/jac/dkx032. J Antimicrob Chemother. 2017. PMID: 28355466 Review.
-
Study on invasive aspergillosis using galactomannan enzyme immunoassay and determining antifungal drug susceptibility among hospitalized patients with hematologic malignancies or candidates for organ transplantation.Microb Pathog. 2020 Oct;147:104382. doi: 10.1016/j.micpath.2020.104382. Epub 2020 Jul 12. Microb Pathog. 2020. PMID: 32663605
-
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12. Clin Microbiol Infect. 2018. PMID: 29544767
-
Invasive aspergillosis in developing countries.Med Mycol. 2011 Apr;49 Suppl 1:S35-47. doi: 10.3109/13693786.2010.505206. Epub 2010 Aug 18. Med Mycol. 2011. PMID: 20718613 Review.
Cited by
-
An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies.Infect Drug Resist. 2020 Jul 14;13:2329-2354. doi: 10.2147/IDR.S254478. eCollection 2020. Infect Drug Resist. 2020. PMID: 32765009 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous